The 340B fights of 2026 are being waged as disputes over fairness and intent. Underneath, they are disputes over data.

We’ve built global highways for approved medicines and left clinical trial access on something closer to dirt roads.

Since taking office, the Trump administration has inflicted chaos on Title X, the only federal program that supports the ...

If the relevant question is how to obtain the greatest health value for the money spent, a cost-effectiveness analysis or ...

The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves ...

The US spends 25 percent of all health care costs on administration, a big part of which involves billing for medical ...

Targeted transparency requirements, clearer guidance on contract pharmacy use, and stronger duplicate-discount safeguards ...

Changing late-life disability and care patterns that may accompany population aging have profound consequences for the nation’s health and related public policies. Drawing on two cross-sectional ...

Regulatory false starts” occur when investments in compliance infrastructure, operational workflow redesign, technology ...

Congress should strengthen the Medicaid safety net by reforming how the federal government funds state Medicaid programs, ...

From 2005 to 2023, per capita health care spending was highest and grew most rapidly among Americans in the top income ...

The American Medical Association now offers ethical guidance to physicians who are considering selling their private ...